Cancer of Unknown Primary (CUP) Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Platinum Compounds, Taxanes, Immune Checkpoint Inhibitors, Antimetabolites, HER2-Directed ADCs/HER2-Directed Biologics, TRK Inhibitors, BRAF/MEK Inhibitors, and Others), By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Age Group (Pediatric and Adults), By Route of Administration (Intravenous and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2026-2034

The global cancer of unknown primary (CUP) therapeutics market size was valued at USD 2.23 billion in 2025. The market is projected to grow from USD 2.38 billion in 2026 to USD 3.91 billion by 2034, exhibiting a CAGR of 6.40% during the forecast period.

The global market comprises systemic treatment options used for patients whose cancer has already spread, while the original tumor site remains unidentified after standard diagnostic evaluation. The market includes chemotherapy, immunotherapy, targeted therapy, and biomarker-guided treatment approaches that help clinicians manage CUP based on tumor biology, histology, molecular profile, and suspected site of origin. As CUP is often diagnosed at an advanced stage and has limited specific approved therapies, due to which the demand for precision oncology tools and tumor-agnostic medicines is increasing. These approaches enable clinicians to guide treatment decisions even when the primary site remains unknown. This shift is supporting market growth as healthcare providers move away from broad empirical Chemotherapy toward more personalized and biomarker-driven treatment decisions.

• For instance, in May 2025, Illumina Inc. expanded its clinical oncology portfolio to advance precision oncology and improve patient access to targeted cancer therapies. Such developments are supporting market expansion and contributing to improved standards of care.

Major players, such as Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, and F. Hoffmann-La Roche Ltd, are streamlining their resources toward research and development, expanding their pipelines, diversifying their offerings, and improving patient outcomes.

CANCER OF UNKNOWN PRIMARY (CUP) THERAPEUTICS MARKET TRENDS

Increasing Shift Toward Molecular Profiling Is an Emerging Trend Observed

A prominent trend in the market is a growing shift toward molecular profiling to guide therapy selection. CUP patients often present with metastatic disease in which the original tumor site cannot be identified despite extensive diagnostic evaluation. In such cases, standard Chemotherapy may not adequately address the underlying biological drivers of the disease, elevating the need for genomic testing, tissue-of-origin analysis, and biomarker-based treatment selection. As molecular diagnostics profiling identifies actionable alterations, such as MSI-H, NTRK fusions, RET alterations, BRAF mutations, and other targetable markers, clinicians can move from broad empirical treatment to more personalized therapy choices.

• For instance, in August 2025, Illumina Inc. launched the next generation of TruSight Oncology 500, its cancer research assay designed for comprehensive genomic profiling. The platform provides laboratories with a molecular tumor profile, advancing therapy selection and clinical trial eligibility. Such advancements in broad tumor profiling can help identify actionable biomarkers in cancers where the primary site remains unclear.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Burden of Metastatic Cancers to Drive Market Growth

The rising clinical burden of metastatic cancers in which the original tumor site remains unidentified even after diagnostic evaluation is a key factor driving the global cancer of unknown primary (CUP) therapeutics market growth. CUP is usually detected after the cancer has already spread, which creates an immediate need for systemic treatment rather than localized therapy. As these patients often require targeted therapies, the demand for effective oncology therapeutics increases. This drives market growth, encouraging oncologists to use broader systemic regimens and precision-medicine approaches to improve patient outcomes.

• For instance, in January 2026, Moderna, Inc. and Merck & Co., Inc. announced five-year data for intismeran autogene in combination with KEYTRUDA in high-risk melanoma, while also noting that eight randomized Phase 2 and Phase 3 trials were underway across multiple tumor types. Such development supports the market as companies are expanding broad oncology immunotherapy and combination-treatment pipelines.

MARKET RESTRAINTS

Limited Availability of CUP-Specific Approved Drugs Restricts Market Growth

The global cancer of unknown primary (CUP) therapeutics market is restrained by the limited availability of therapies approved specifically for CUP treatment. Since the primary tumor site remains unidentified, drug selection is often based on histology, clinical presentation, suspected tissue of origin, or actionable biomarkers rather than a clearly defined cancer type. This limits the development of dedicated CUP-labeled drugs and keeps many unfavorable CUP patients dependent on empirical chemotherapy. These factors collectively result in inconsistent treatment outcomes, limited product differentiation, and adoption of newer targeted or immunotherapy-based options that depend heavily on access to molecular testing, biomarker eligibility, and reimbursement support.

• For instance, in 2025, Nature Reviews Clinical Oncology published a review stating that Cancer of Unknown Primary (CUP) continues to represent a major diagnostic challenge with poor prognosis, and standard empirical Chemotherapy provides limited benefit. Many CUP patients still lack a clearly identified primary tumor and therefore cannot always receive site-specific treatment.

MARKET OPPORTUNITIES

Expansion of Precision Oncology to Offer Several Growth Opportunities

The global market presents strong growth opportunities through the expansion of precision oncology. CUP patients often present with metastatic disease in which the original tumor site cannot be identified, making treatment decisions difficult when physicians rely only on broad Chemotherapy or presumed tissue origin. As molecular profiling, next-generation sequencing, and biomarker testing become more available, clinicians can identify actionable alterations and select targeted therapies, immunotherapies, or clinical trials more accurately. This creates a growth opportunity for drug developers and diagnostic companies, as CUP treatment can shift from a generalized approach to a more personalized model based on tumor biology, improving treatment selection and supporting the wider use of tumor-agnostic oncology products.

• For instance, in August 2025, Caris Life Sciences published a study showing that its AI-based tissue-of-origin prediction tool, Caris GPSai, could improve diagnostic accuracy for cancers of unknown primary origin and misclassified tumors.

MARKET CHALLENGES

Uptake of Newer Targeted or Immunotherapy-Based Options to Deter Industry Development

The global cancer of unknown primary (CUP) therapeutics market faces a major challenge as many unfavorable CUP patients are still treated with empirical platinum-based Chemotherapy when the primary tumor site and actionable biomarkers cannot be clearly identified. This creates a treatment gap ass Chemotherapy is often selected broadly rather than matched to the tumor’s exact biology. As a result, clinical outcomes frequently remain inconsistent, treatment toxicity may limit continuation, and the uptake of newer targeted or immunotherapy-based options depends heavily on access to molecular testing and biomarker eligibility. This challenge slows market growth as the lack of clear CUP-specific treatment pathways leaves a large share of patients dependent on older systemic regimens instead of precision-guided therapies.

• For instance, in 2025, Nature Reviews Clinical Oncology reported that CUP continues to represent a major diagnostic challenge with poor prognosis, while standard empirical Chemotherapy provides limited benefit. This highlights the key market challenge as continued reliance on broad Chemotherapy reduces the effectiveness of treatment personalization and highlights the unmet need for stronger CUP-specific therapeutic strategies.

Segmentation Analysis

By Drug Class

Platinum Compounds Led the Segment due to Established Physician Familiarity

Based on drug class, the market is categorized into platinum compounds, taxanes, immune checkpoint inhibitors, antimetabolites, HER2-directed ADCs/HER2-directed biologics, TRK inhibitors, BRAF/MEK inhibitors, and others.

Platinum compounds dominated the CUP therapeutics market. Platinum-based Chemotherapy remains one of the most widely used systemic treatment approaches for unfavorable CUP cases. Since the primary tumor site is often unknown, physicians commonly use broad-acting regimens that can treat metastatic disease across multiple possible tumor origins. The segment also benefits from wide hospital availability, established physician familiarity, and use in both empirical and site-directed treatment strategies.  

• For instance, in June 2024, AstraZeneca received approval from the U.S. FDA for IMFINZI plus chemotherapy for adult patients with mismatch repair-deficient advanced or recurrent endometrial cancer, using carboplatin and paclitaxel followed by IMFINZI monotherapy. This supports the dominance of platinum compounds, as carboplatin remains a key backbone therapy in advanced solid tumor treatment combinations.

The HER2-directed ADCs/HER2-directed biologics segment is expected to grow at a CAGR of 11.24% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Therapy Type

High Treatment Volume of Chemotherapy to Propel Segment Growth

Based on therapy type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.

In 2025, chemotherapy is estimated to dominate the market. Most CUP patients need systemic treatment at the time of diagnosis, and many do not present with an immediately actionable biomarker or a clearly identified primary tumor. As chemotherapy circulates throughout the body, it remains useful for patients with widespread metastatic disease and uncertain tumor origin. Therefore, chemotherapy continues to hold the leading position, while precision therapies are growing as add-on or selected-patient options. The American Cancer Society also notes that Chemotherapy is recommended for most CUP patients, as CUP is often present in many areas of the body.

• For instance, in August 2024, GSK plc announced that the U.S. FDA expanded JEMPERLI in combination to include These developments reflect the continued importance of chemotherapy-based regimens in advanced solid tumors, supporting the chemotherapy segment’s leadership in CUP, where broad systemic treatment is often required.

The targeted therapy segment is projected to grow at a CAGR of 10.42% during the forecast period.

By Age Group

Broader Use of Systemic Therapies Boosted Adult Segment Growth

Based on age group, the market is segmented into pediatric and adult.

In 2025, adults accounted for the largest cancer of unknown primary (CUP) therapeutics market share, as CUP is primarily treated as an adult oncology condition. Most commercial oncology drugs used in CUP-related treatment pathways are developed, approved, and prescribed primarily for adult solid tumors. The adult segment also benefits from higher diagnosis rates, broader use of systemic therapies, and stronger access to molecular testing and hospital oncology care. In addition, ongoing product launches and regulatory approvals for adult oncology therapies continue to strengthen the segment’s dominance in the market.

• For instance, in December 2024, Bristol Myers Squibb announced U.S. FDA approval of OPDIVO QVANTI for subcutaneous use across most previously approved adult solid tumor indications.

The pediatric segment is projected to grow at a CAGR of 8.15% during the forecast period.

By Route of Administration

Intravenous Segment Dominated due to Combination Treatment Schedules

Based on route of administration, the market is segmented into intravenous and others.

In 2025, intravenous held a dominant position in the market. Many leading treatment options, including platinum chemotherapy, taxanes, immune checkpoint inhibitors, and several antibody-drug conjugates, are administered through intravenous infusion in oncology care settings. CUP patients often require hospital- or clinic-based systemic therapy due to advanced disease, monitoring needs, and combination treatment schedules. These factors support the higher use of intravenous therapies across CUP treatment pathways. In addition, a larger portion of patients continues to depend on infused chemotherapy and immunotherapy regimens.

• For instance, in September 2025, Daiichi Sankyo, in collaboration with AstraZeneca PLC, announced that the EMA validated a Type II variation application for ENHERTU® for previously treated HER2-positive metastatic solid tumors, noting that it could become the first HER2-directed medicine and antibody-drug conjugate with a tumor-agnostic indication in the EU if approved.

The others segment is projected to grow at a CAGR of 9.06% during the forecast period.

By Distribution Channel

Hospital Pharmacies to Lead due to Rising Prevalence of Advanced Metastatic Disease

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment is projected to dominate the market as CUP treatment is usually managed in oncology hospitals, cancer centers, and infusion clinics, where physicians need access to chemotherapy, immunotherapy, biologics, supportive medicines, and monitoring services. Since many CUP patients present with advanced metastatic disease, treatment often requires specialist supervision, infusion infrastructure, toxicity management, and multidisciplinary decision-making. These factors make hospital pharmacies the main channel for dispensing and managing high-cost injectable oncology medicines. Retail and online pharmacies play a smaller role, mainly supporting selected oral therapies and supportive care medications.

• For instance, in September 2025, Merck & Co., Inc. announced U.S. FDA approval of KEYTRUDA QLEX for subcutaneous Administration across most solid tumor indications, noting that the therapy must be administered by a healthcare provider. This supports the hospital pharmacy segment, as major oncology immunotherapies continue to be supplied and administered in supervised healthcare settings, reinforcing the role of hospital-based oncology channels in advanced cancer treatment.

The online pharmacies segment is projected to grow at a CAGR of 11.28% over the study period.

Cancer of Unknown Primary (CUP) Therapeutics Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 0.90 billion, and maintained its leading position in 2025 at USD 0.95 billion. The regional market is witnessing robust growth due to strong access to oncology specialists, molecular profiling, and immunotherapy/targeted therapy options. High cancer diagnosis rates and wider use of next-generation sequencing are improving treatment selection for CUP patients. Strong reimbursement and the availability of clinical trials further improve the adoption of advanced therapeutics.

U.S. Cancer of Unknown Primary (CUP) Therapeutics Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is poised to reach around USD 0.93 billion by 2026, accounting for roughly 39.06% of the global sales.

Europe

Europe is projected to grow at a CAGR of 5.79% over the coming years, the second-highest among all regions. The market is expected to reach a valuation of USD 0.63 billion by 2026. Structured cancer care pathways, national oncology programs, and increasing use of biomarker-based treatment support growth-based treatment. As European cancer centers continue to implement molecular tumor boards and precision oncology testing, CUP patients are increasingly being evaluated for actionable mutations. This trend is driving demand for targeted therapies and immune checkpoint inhibitors across the region.

U.K. Cancer of Unknown Primary (CUP) Therapeutics Market

The U.K. market is estimated to reach around USD 0.10 billion by 2026, representing roughly 4.30% of the global sales.

Germany Cancer of Unknown Primary (CUP) Therapeutics Market

Germany's market is projected to reach approximately USD 0.14 billion by 2026, equivalent to around 5.79% of the global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.53 billion by 2026 and secure the position of the third-largest region in the market. The market is expanding due to rising cancer burden, improving hospital oncology infrastructure, and growing access to advanced diagnostics in the region. Expanding pharma investment and clinical trials also support regional Growth.

Japan Cancer of Unknown Primary (CUP) Therapeutics Market

The Japanese market is estimated to touch around USD 0.13 billion by 2026, accounting for approximately 5.49% of the global sales.

China Cancer of Unknown Primary (CUP) Therapeutics Market

China's market is projected to be among the largest worldwide. The market is expected to reach USD 0.18 billion by 2026, accounting for approximately 7.51% of global sales.

India Cancer of Unknown Primary (CUP) Therapeutics Market

The Indian market is estimated to reach around USD 0.05 billion by 2026, accounting for roughly 2.27% of global revenues.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.13 billion by 2026, driven by improving access to cancer diagnosis, Chemotherapy, and specialty oncology services in large markets. In the Middle East & Africa, the GCC is set to reach USD 0.04 billion by 2026.

South Africa Cancer of Unknown Primary (CUP) Therapeutics Market

The South African market is projected to reach approximately USD 0.02 billion by 2026, accounting for roughly 0.72% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Companies Focus on Diagnostic-Linked Treatment Approaches to Strengthen Their Market Position

The global cancer of unknown primary (CUP) therapeutics market is moderately fragmented, with companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, and Eli Lilly and Company holding strong positions in the market. These companies have gained prominence due to their broad oncology portfolios, strong presence in metastatic solid tumor treatment, and growing focus on tumor-agnostic and biomarker-defined therapies. Strategic product approvals, label expansions, clinical trials, and diagnostic-linked treatment approaches are further helping these companies improve their market presence.

• For instance, in April 2024, AstraZeneca PLC and Daiichi Sankyo Company, Limited announced that ENHERTU was approved in the U.S. as the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors. The development strengthened the role of HER2-directed ADCs in precision oncology. It supported the use of biomarker-led treatment approaches in cancers where treatment selection may depend more on molecular profile than tumor origin.

Other notable participants in the market include Pfizer Inc., Sanofi, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Limited, and Viatris Inc. These companies are expected to remain important market participants as Chemotherapy continues to be widely used in unfavorable CUP cases, especially when actionable biomarkers are not identified or when access to advanced molecular testing is limited. The rest of the market remains fragmented among generic oncology suppliers, regional manufacturers, and hospital-based injectable drug providers serving high-volume chemotherapy demand across developed and emerging healthcare markets.

LIST OF KEY CANCER OF UNKOWN PRIMARY (CUP) THERAPEUTICS COMPANIES PROFILED

• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• AstraZeneca PLC (U.K.)
• Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Eli Lilly and Company (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi (France)

KEY INDUSTRY DEVELOPMENTS

• September 2025: Merck & Co., Inc., received approval from the U.S. FDA for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous Administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
• May 2025: Illumina Inc. expanded its clinical oncology portfolio, unlocking the next generation of solutions to advance precision oncology and improve the standard of care. The broad range of clinical offerings aims to accelerate access to precision oncology for a broader range of cancer patients.
• May 2025: Halozyme Therapeutics, Inc., in collaboration with Bristol Myers Squibb, received approval from the European Commission (EC) for a new Opdivo (nivolumab) subcutaneous formulation for use across multiple adult solid tumor indications. The therapy is approved as monotherapy, maintenance therapy following intravenous nivolumab plus Yervoy (ipilimumab) combination treatment, or in combination with Chemotherapy or cabozantinib.
• April 2025: Bayer AG received full approval from the U.S. FDA for VITRAKVI (larotrectinib), a TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. The therapy is approved for patients with metastatic disease or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose disease has progressed following treatment.
• April 2021: Ono Pharmaceutical Co., Ltd. submitted a supplemental application in Japan for Opdivo Intravenous Infusion, a human anti-human PD-1 monoclonal antibody, seeking expanded approval for the treatment of cancer of unknown primary through a partial amendment to its manufacturing and marketing authorization.

REPORT COVERAGE

The report provides a comprehensive analysis of the global cancer of unknown primary (CUP) therapeutics market. It covers detailed market analysis across drug class, therapy type, age group, route of administration, and distribution channel. It reports also includes the factors driving the growth of the market, highlighting growth opportunities and challenges, while also assessing the role of chemotherapy, targeted therapy, immunotherapy, and supportive treatment approaches in current clinical practice. The study further provides regional insights across key geographies, competitive landscape analysis, company profiling, recent developments, and evaluation of the major factors driving, restraining, and shaping future opportunities in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation